Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of different hypoglycemic drugs on metabolic indexes in type 2 diabetes
ChiCTR2200066604Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Dec 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin and selenium yeast in type 2 diabetes mellitus (T2DM) and atherosclerotic disease (3 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoints: Glycated hemoglobin (HbA1c), Biochemical routine (blood glucose, liver and kidney function, blood lipids, electrolytes) and 1 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
metforminselenium yeast
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2200066604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066604.